Biogen CEO Buys $19 k Shares Amid Routine Insider Flurry – Investors Eye Pipeline, Not Trades
Biogen CEO’s February trades show confidence, with a modest net purchase amid routine vesting—insider activity signals growth optimism, not market moves.
8 minutes to read

